Abstract
We recently read the retrospective research paper titled, ‘The Impact of Beta Blockers on Survival Outcomes in Patients With Non-small-cell Lung Cancer Treated With Immune Checkpoint Inhibitors,’ by Oh et al. in Clinical Lung Cancer.1 We thought that the result of the study was very interesting and informative for thoracic oncologists involved in the treatment of patients with non-small-cell lung cancer (NSCLC). The authors examined the impact of beta blocker use on clinical outcomes, progression-free survival (PFS), and overall survival in 109 patients with NSCLC treated with cancer immunotherapy and revealed that beta blocker use was associated with improved PFS in these patients (yes vs.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
